NurExone Biologic
EV-based Drug Platform to Treat Damage in the Central Nerve System
StartupNurExone Biologic is a Haifa-based startup in the Health Tech & Life Sciences sector, established in 2020. EV-based Drug Platform to Treat Damage in the Central Nerve System . The company has raised a total of $2.84M across 3 funding rounds, currently at the Public stage. Key investors include Undisclosed Investor(s). The company has 11-50 employees. Core technologies: Biologicals.
With $2.84M in total funding, NurExone Biologic is a Public-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent.
- StagePublic
- ProductClinical Trial
- ModelB2B
- Employees11-50
- HQHaifa
- Last Round$838K
- Undisclosed Investor(s)
120 articles covered by sources including finance.yahoo.com,
www.globenewswire.com,
www.jpost.com,
www.newswire.ca.
What does NurExone Biologic do?
Nurexone is aiming to revolutionize recovery from nervous system injuries by regenerating and rewiring of neurons. The company is developing a revolutionary biological extracellular vesicles-based technology drug platform to treat damage in the Central Nerve System (CNS). NurExone’s novel approach to SCI treatment is based on the perspective that intranasal exosome administration has broad potential and offers an alternative to other treatments that are under development to treat SCI. Extensive research, conducted at Prof. Shulamit Levenberg’s lab at the Technion, Haifa in collaboration with Prof. Danny Offen from Tel Aviv University tested a novel proprietary treatment using intranasal administration of Exosomes derived from mesenchymal stem cells. Their exosomes were loaded with PTEN siRNA to target complete spinal cord lesion in rats. The research showed significant functional recovery.
How much funding has NurExone Biologic raised?
NurExone Biologic has raised $2.84M in total funding across 3 rounds. The company is currently at the Public stage. Key investors include Undisclosed Investor(s).
What sector is NurExone Biologic in?
NurExone Biologic operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.
Where is NurExone Biologic located?
NurExone Biologic is based in Haifa, Israel.